Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q1 2016 · 10-Q
Revenue$1.85M$1.85M+84.8% vs Q1 2015 Net Income-$17.11M-$17.11MN/M vs Q1 2015 EPS Diluted-$0.19-$0.19N/M vs Q1 2015 Gross Profit$1,848,000+84.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flow-$14,313,000N/M Free Cash Flowderived-$14,896,000N/M Margins · derivedGross margin100.0%−0.0 pt vs Q1 2015
Operating margin-1285.6%+64.6 pt vs Q1 2015
Net margin-926.0%+90.8 pt vs Q1 2015
ended Mar 31, 2016 · filed May 10, 2016 · 40 d after period end